Log in to save to my catalogue

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosi...

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9289708

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa

About this item

Full title

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa

Publisher

Switzerland: John Wiley & Sons, Inc

Journal title

Journal of the International AIDS Society, 2022-07, Vol.25 (7), p.e25961-n/a

Language

English

Formats

Publication information

Publisher

Switzerland: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Introduction
Dolutegravir is being scaled up globally as part of antiretroviral therapy (ART), but for people with HIV and tuberculosis co‐infection, its use is complicated by a drug–drug interaction with rifampicin requiring an additional daily dose of dolutegravir. This represents a disadvantage over efavirenz, which does not have a major drug...

Alternative Titles

Full title

Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9289708

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9289708

Other Identifiers

ISSN

1758-2652

E-ISSN

1758-2652

DOI

10.1002/jia2.25961

How to access this item